HUTCHMED (China) Limited ADR (HCM)

Precedente Chiudi:

$19.45

Aprire:

$19.2

Volume 24 ore:

34,624

Capitalizzazione di mercato:

$3.31B

Reddito:

$838.00M

Utile/perdita netta:

$100.78M

Rapporto P/E:

-77.73

EPS:

-0.25

Flusso di cassa netto:

$186.65M

1 W Prestazione:

+3.46%

1M Prestazione:

+15.06%

6M Prestazione:

-0.46%

1 anno Prestazione:

+25.06%

Intervallo 1D:

$19.19

$19.51

Portata 52W:

$10.68

$20.73

HUTCHMED (China) Limited ADR Stock (HCM) Company Profile

Nome

HUTCHMED (China) Limited ADR

Settore

Healthcare (1223)

Industria

Drug Manufacturers - Specialty & Generic (3)

Telefono

852 2121 8200

Indirizzo

Hutchison House, 22nd Floor 10 Harcourt Road, Central

Dipendente

590

Cinguettio

@hchimed

Prossima data di guadagno

2024-06-05

Ultimi documenti SEC

HCM's Discussions on Twitter

HUTCHMED (China) Limited ADR Stock (HCM) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-11-24	Aggiornamento	Deutsche Bank	Hold → Buy
2022-05-04	Downgrade	Deutsche Bank	Buy → Hold
2021-09-22	Downgrade	Goldman	Buy → Neutral
2021-08-03	Iniziato	Jefferies	Buy
2020-10-02	Iniziato	Deutsche Bank	Buy
2020-03-13	Iniziato	Cantor Fitzgerald	Overweight
2020-02-20	Iniziato	Goldman	Buy
2019-11-19	Iniziato	CLSA	Buy
2019-10-23	Reiterato	BofA/Merrill	Buy
2019-07-05	Iniziato	Macquarie	Outperform

Mostra tutto

HUTCHMED (China) Limited ADR Borsa (HCM) Ultime notizie

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

GlobeNewswire Inc.

HUTCHMED (HCM) Upgraded to Buy: Here's What You Should Know

Zacks Investment Research

Does HUTCHMED (HCM) Have the Potential to Rally 38.13% as Wall Street Analysts Expect?

Zacks Investment Research

HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda

GlobeNewswire Inc.

HUTCHMED Highlights Data to be Presented at AACR Congress 2024

GlobeNewswire Inc.

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

GlobeNewswire Inc.

HUTCHMED (China) Limited ADR Azioni (HCM) Dati Finanziari

HUTCHMED (China) Limited ADR (HCM) Reddito 2024

HUTCHMED (China) Limited ADR (HCM) Reddito netto 2024

HUTCHMED (China) Limited ADR (HCM) Flusso di cassa 2024

HUTCHMED (China) Limited ADR (HCM) Utile per azione 2024